1. Market Research
  2. > Pathology
16 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028

  • $ 10995
  • April 2020
  • 204 pages

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028 Summary Age-related macular degeneration (AMD) is an eye condition that is characterized by the gradual deterioration ...

  • Lymphoma
  • Ophthalmology
  • Targeted Therapy
  • Therapy
  • Australasia

Graft Versus Host Disease (GvHD): Forecast in Asia-Pacific Markets to 2028

  • $ 8995
  • July 2020
  • 111 pages

ACHIEVING APPROVAL FOR CGVHD WITHOUT SIGNIFICANT CLINICAL EVIDENCE IS PARTIALLY DUE TO ITS MOA AND THE SUBSTANTIAL CLINICAL STUDIES CONDUCTED OF IMBRUVICA IN OTHER HEMATOLOGICAL INDICATIONS, INCLUDING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MANTLE CELL LYMPHOMA (MCL).

  • Lymphoma
  • Therapy
  • Transplantation
  • Australasia
  • Forecast

Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2027

  • $ 10995
  • January 2019
  • 201 pages

ALTHOUGH CELLTRION' S TRUXIMA WAS SIMILARLY TREATED BY THE FDA, THE COMPANY COMPLIED WITH REQUESTS FOR ADDITIONAL DATA AND IN NOVEMBER 2018, CELLTRION' S TRUXIMA WAS APPROVED, BUT ONLY FOR THE TREATMENT OF B-CELL NON-HODGKIN AND FOLLICULAR LYMPHOMAS (CELLTRION, PRESS RELEASE, ## NOV

  • Biosimilar
  • Hospital
  • Lymphoma
  • Therapy
  • Australasia

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Australia

  • $ 1995
  • November 2019
  • 180 pages

It also discontinued GSK-## in Phase I stage of development for follicular lymphoma, diffuse large Bcell lymphoma, solid tumor, and refractory multiple myeloma.

  • Lymphoma
  • Medical Device
  • Medical Equipment
  • Pharmaceutical
  • Australasia

Human T-Lymphotropic Virus (HTLV) Test (In Vitro Diagnostics) - Global Market Analysis and Forecast Model

  • $ 7500
  • December 2018
  • 1 pages

Specifically, sources indicate that up to ##-##% of patients infected with HTLV-I develop adult T-cell Leukemia/ Lymphoma (ATLL) or HTLV-I-associated Myelopathy/ Tropical Spastic Paraparesis (HAM/ TSP).

  • Diagnostics
  • Lymphoma
  • Australasia
  • World
  • Supply

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • February 2017
  • 403 pages

HOWEVER, PATIENTS WITH RA ARE KNOWN TO BE AT A HIGHER RISK FOR DEVELOPING LYMPHOMA.

  • Biosimilar
  • Epidemiology
  • Hospital
  • Lymphoma
  • Australasia

Australia General Surgery Market Outlook to 2023 - Aesthetic Lasers and Energy Devices, Bariatric Surgery Devices, Biopsy Devices, Bronchoscopes, Colonoscopes, Cystoscopes, Duodenoscopes, Endoscopy Fluid Management Systems and Others

  • $ 5995
  • May 2017
  • 564 pages

LYMPHOMA CONSUMERS AND HEALTH PROFESSIONALS ARE ADVISED THAT THE TGA HAS CONTINUED TO MONITOR THE ASSOCIATION BETWEEN ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) AND BREAST IMPLANTS SINCE WE PUBLISHED A SAFETY COMMUNICATION REGARDING THIS ISSUE ON ## JANUARY 2011.

  • Biopsy
  • Endoscope
  • Lymphoma
  • Australasia
  • Australia

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2026

  • $ 10995
  • September 2017
  • 433 pages

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2026 Summary Melanoma is the deadliest and most aggressive form of skin cancer. Melanoma is rare compared to other major cancer indications, ...

  • Hospital
  • Lymphoma
  • Therapy
  • Australasia
  • Merck & Co., Inc.

Australia In Vitro Diagnostics Market Outlook to 2025 - Cardiac Disease, Clinical Chemistry, Hematological Disorders and Others.

  • $ 5995
  • April 2020
  • 503 pages

ASSOCIATE PROFESSOR WIEGMANS SAID THE STUDY COULD HAVE IMPLICATIONS FOR SEVERAL OTHER CANCERS WHERE DOXORUBICIN WAS USED, SUCH AS BLADDER, STOMACH, LUNG, OVARIAN, AND THYROID CANCERS AND SOME TYPES OF LEUKAEMIA AND HODGKIN S LYMPHOMA.

  • Infectious Disease
  • Lymphoma
  • Australasia
  • Australia
  • Oceania

Australia Wound Care Management Market Outlook to 2025 - Advanced Wound Management, Compression Therapy, Negative Pressure Wound Therapy (NPWT), Ostomy Drainage Bags and Others

  • $ 5995
  • July 2019
  • 352 pages

Australia Wound Care Management Market Outlook to 2025 - Advanced Wound Management, Compression Therapy, Negative Pressure Wound Therapy (NPWT), Ostomy Drainage Bags and Others Summary GlobalData’s ...

  • Lymphoma
  • Wound Care
  • Australasia
  • Australia
  • Oceania

CSL Ltd (CSL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • November 2018
  • 95 pages

CSL Ltd (CSL) Pharmaceuticals & Healthcare - Deals and Alliances Profile Report Code: GDPH##D Published: November 2018 CSL Ltd (CSL) discovers, develops, manufactures, markets and distributes biopharmaceuticals and related products.

  • Lymphoma
  • Pharmaceutical
  • Vaccine
  • Australasia
  • CSL Limited

Rosetta Genomics Ltd - Medical Equipment - Deals and Alliances Profile

  • $ 250
  • December 2018
  • 59 pages

lymphomas.

  • Genomics
  • Lymphoma
  • Medical Device
  • Australasia
  • Rosetta Genomics Ltd.

Peter MacCallum Cancer Centre - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • November 2018
  • 28 pages

They are combining Dinaciclib with the anti-PD## therapy, Keytruda, in relapsed lymphoma, myeloma and chronic lymphocytic leukaemia.

  • Health Services
  • Lymphoma
  • Pharmaceutical
  • Specialty Hospital
  • Australasia

EnGeneIC Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • November 2018
  • 19 pages

The company' s product Velcade is used for the treatment of multiple myeloma and relapsed mantle cell lymphoma.

  • Lymphoma
  • Medical Biotechnology
  • Pharmaceutical
  • Australasia
  • EnGeneIC Ltd

Specialised Therapeutics Australia Pty Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • October 2018
  • 25 pages

Ariad' s pipeline portfolio comprises three promising molecules including Iclusig, a novel oral multi-targeted kinase inhibitor; Brigatinib, an anaplastic lymphoma kinase inhibitor; and AP##, a drug candidate, for the treatment of patients with NSCLC with specific mutations in the EG

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Australasia
  • Australia

Australia In Vitro Diagnostics (IVD) Market Outlook to 2024 - Clinical Chemistry, Genetic Testing, Hematology, Histology and Cytology, Immuno Chemistry, Infectious Diagnostics and Microbiology Culture

  • $ 5995
  • December 2017
  • 544 pages

TRANSPLANTS ARE USED TO REPLACE DISEASED OR CANCEROUS BONE MARROW WITH HEALTHY BONE MARROW TO TREAT A RANGE OF DISEASES INCLUDING LEUKEMIA, LYMPHOMA AND IMMUNE DEFICIENCY DISORDERS.

  • In Vitro Diagnostic Reagent
  • Lymphoma
  • Australasia
  • Australia
  • Oceania


View report >

Cancer Statistics

  • February 2020
  • 66 pages

Salivary gland Polycythaemia vera Oropharynx Other lymphomas Thymus Eye Nose, nasal cavities, middle ear and accessory sinuses Larynx Other endocrine glands Skin of anus (including perineum, perianal skin) Nasopharynx Malignancy of histiocytes and accessory lymphoid cells Unspecified sites

  • Cancer
  • Lymphoma
  • Pathology
  • Australasia
  • Demographic

Cancer Statistics June 2019

Cancer Statistics January 2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on